Performance of mCIM/eCIM in Enterobacterales strains co-encoding NDM and OXA-48-like ...

The Diagnostic Gap in Combatting Carbapenem-Resistant Enterobacterales

For clinicians working in intensive care units, the margin for error when treating Carbapenem-resistant Enterobacterales (CRE) is razor-thin. A new analysis published in the Journal of Clinical Microbiology on October 30, 2026, reveals a troubling blind spot in the tools hospitals rely on to identify these dangerous infections. As researchers found, the phenotypic tests clinicians trust to guide antibiotic therapy—the modified carbapenem inactivation method (mCIM) and the EDTA-modified CIM (eCIM)—frequently misidentify the specific resistance mechanisms at play in complex, multi-carbapenemase-producing strains.

The study, which examined 172 genotypically confirmed isolates, highlights a growing clinical challenge: as bacteria evolve to carry multiple carbapenemases, our standard diagnostic assays are struggling to keep pace. While these tests have historically been the workhorses of the microbiology lab, their performance in the face of co-encoding strains—specifically those harboring both NDM and OXA-48-like enzymes—is far from foolproof.

When Standard Tests Falter

The research utilized a significant cohort of perirectal swabs collected from two intensive care units at a hospital in South India. The breakdown of the samples provides a clear picture of the target population: 53.5% were Escherichia coli, 41.3% were Klebsiella pneumoniae, and the remaining 5.3% were Enterobacter species. Among these, 112 isolates carried NDM alone, 23 carried OXA-48-like alone, and 37 were found to be dual-producers of both.

The performance data reveals a distinct hierarchy of accuracy. For NDM-encoding isolates, mCIM showed a high positivity rate of 98.2%. However, for those encoding OXA-48-like, the test stumbled, returning a positivity rate of just 47.8%. The implications for patient care are significant. When compared to molecular carbapenemase gene detection, the mCIM/eCIM workflow frequently misclassified OXA-48-like encoders as having a metallo-β-lactamase (MBL) or as lacking a carbapenemase.

For the 37 isolates encoding both NDM and OXA-48-like, the assay typically categorized them as MBL producers. While this classification might seem sufficient, it masks the underlying complexity of the resistance, potentially leading to suboptimal antibiotic choices in critical care settings where precise, targeted therapy is the difference between recovery and systemic failure.

The Geographic Variable in Resistance

Why do these tests perform inconsistently? The researchers suggest that the efficacy of mCIM and eCIM may vary geographically due to variable activity, distribution, and combinations of carbapenemases. As these resistance genes migrate and recombine, the phenotypic expression of the bacteria changes, rendering static diagnostic protocols increasingly vulnerable to error.

This is not merely a laboratory concern; it is a public health burden. Infections caused by CRE are associated with substantial adverse health outcomes. When a diagnostic test misclassifies an isolate, the window for effective intervention narrows. The need for rapid and accurate detection is universal, but this study suggests that the performance of mCIM and eCIM remains insufficiently defined for these strains.

The Path Toward Molecular Precision

The findings serve as a stark reminder of the limitations inherent in phenotypic assays. While these methods remain accessible and cost-effective for many institutions, they cannot match the precision of molecular gene detection. As the study published in the Journal of Clinical Microbiology emphasizes, understanding the mechanisms behind this variable activity is the next frontier for hospital diagnostics.

For the healthcare sector, the takeaway is clear: phenotypic results must be interpreted with caution, especially in regions where co-encoding strains are prevalent. Relying solely on mCIM/eCIM without considering the potential for misclassification could lead to the unintended promotion of further resistance through inappropriate antibiotic pressure. As genomic surveillance becomes more integrated into hospital protocols, the diagnostic landscape is likely to shift toward molecular methods that can peer directly into the genetic machinery of the pathogen, rather than simply observing its outward behavior in a petri dish.

Worth a look